Yahoo Finance

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant Nantes, France – June 5, 2024, 7:30am CET – OSE ...
Business Insider

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20 th Congress of ECCO NANTES, France – February 24, 2025, 7:30am CET - OSE ...
Fierce Biotech

OSE narrows focus to conserve cash at expense of wider pipeline

OSE Immunotherapeutics is prioritizing its lung cancer med Tedopi and shifting the strategy for its ulcerative colitis (UC) ...
Yahoo Finance

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis

Lusvertikimab demonstrates significant efficacy during the 10 week-induction phase of treatment, in the randomized double-blind CotiKis phase 2 study Favorable safety and tolerability profile in the ...
manilatimes

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of ...

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis Lusvertikimab ...
manilatimes

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

NANTES, France - March 26, 2025, 6:15 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and ...
PharmiWeb

OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology

Nantes, France – February 22, 2023, 6:00 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the online publication in the peer-reviewed ‘The Journal of Immunology’ ...
Wall Street Journal

OSE Immunotherapeutics S.A.

1 Day OSE -2.53% DJIA -1.14% Russell 2K 0.22% Health Care/Life Sciences 1.27% ...
Business Wire

Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

PARIS & NANTES, France--(BUSINESS WIRE)--Regulatory News: Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), a French ...
Investing

OSE Immunotherapeutics appoints Marc Le Bozec as interim CEO

NANTES, France - OSE Immunotherapeutics (EURONEXT:OSE) announced Thursday the appointment of Marc Le Bozec as interim Chief Executive Officer, following the termination of Nicolas Poirier from the CEO ...
Business Wire

OSE Immunotherapeutics and Nantes University Hospital Present Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal ...

NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) and Nantes University Hospital presented positive interim data analysis from ...